申请人:Tibotec Pharmaceuticals Ltd
公开号:US07659245B2
公开(公告)日:2010-02-09
Compounds of the formula I:
and N-oxides, salts, and stereoisomers thereof
wherein
A is OR1, NHS(═O)pR2; wherein;
R1 is hydrogen, C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkylene-heterocyclyl;
R2 is C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl;
p is independently 1 or 2;
n is 3, 4, 5 or 6;
denotes an optional double bond;
L is N or CRz;
Rz is H or forms a double bond with the asterisked carbon;
Rq is H or when L is CRz, Rq can also be C1-C6alkyl;
Rr is quinazolinyl, optionally substituted with one two or three substituents each independently selected from C1-C6 alkyl, C1-C6alkoxy, hydroxyl, halo, haloC1-C6alkyl, amino, mono- or dialkylamino, mono- or dialkylaminocarbonyl, C1-C6alkyl-carbonylamino, C0-C3alkylenecarbocyclyl and C0-C3 alkyleneheterocyclyl;
R5 is hydrogen, C1-C6alkyl, C1-C6alkoxyC1-C6alkyl or C3-C7cycloalkyl;
R6 is hydrogen, C1-C6alkyl, C1-C6alkoxy, C0-C3alkylenecarbocyclyl, C0-C3alkylene-heterocyclyl, hydroxy, bromo, chloro or fluoro have utility in the treatment or prophylaxis of flaviviral infections such as HCV.
化合物I的公式:及其N-氧化物,盐和立体异构体,其中A为OR1,NHS(═O)pR2;其中;R1为氢,C1-C6烷基,C0-C3烷基环烷基,C0-C3烷基-杂环烷基;R2为C1-C6烷基,C0-C3烷基环烷基,C0-C3烷基杂环烷基;p独立地为1或2;n为3、4、5或6;表示可选的双键;L为N或CRz;Rz为H或与星号标记的碳形成双键;Rq为H或当L为CRz时,Rq也可以是C1-C6烷基;Rr为喹唑啉基,可选地被一个、两个或三个取代基取代,每个取代基独立地选自C1-C6烷基、C1-C6烷氧基、羟基、卤素、卤素C1-C6烷基、氨基、单烷基或二烷基氨基、单烷基或二烷基氨基羰基、C1-C6烷基-羰基氨基、C0-C3烷基环烷基和C0-C3烷基杂环烷基;R5为氢,C1-C6烷基,C1-C6烷氧基C1-C6烷基或C3-C7环烷基;R6为氢,C1-C6烷基,C1-C6烷氧基,C0-C3烷基环烷基,C0-C3烷基-杂环烷基,羟基,溴,氯或氟在治疗或预防黄病毒感染(如HCV)方面具有用途。